Skip to content

FDA 2024 Animal Drug User Fee Educational Conference – Part 3



    Lesson Content:

    Target Animal Safety Technical Section Overview, Target Animal Effectiveness

    Prajwal Regmi
    Veterinary Medical Officer
    Office of New Animal Drug Evaluation
    Center for Veterinary Medicine, FDA

    Clinical Pharmacology

    Mark Heit
    Clinical Pharmacology Team
    Office of New Animal Drug Evaluation
    Center for Veterinary Medicine, FDA

    TAS & Effectiveness Best Practices

    Cheryl Johnson
    Veterinary Medical Officer
    Office of New Animal Drug Evaluation
    Center for Veterinary Medicine, FDA

    TAS & Effectiveness Hot Topics

    Andrew Fidler
    Veterinary Medical Officer
    Office of New Animal Drug Evaluation
    Center for Veterinary Medicine, FDA

    Chemistry, Manufacturing and Controls Technical Section Overview

    Peter Bryk
    Office of New Animal Drug Evaluation
    Center for Veterinary Medicine, FDA

    Abstract

    This webinar provides an in-depth exploration of key technical sections essential for new animal drug approvals, including target animal safety, effectiveness, and chemistry, manufacturing, and controls (CMC). It emphasizes the critical importance of establishing a margin of safety for target animals and demonstrating the drug’s intended effect through robust studies. The discussion highlights the role of pharmacology in understanding drug behavior, optimizing formulations, and extending study results. Best practices for submitting high-quality information are detailed, stressing clear communication with the Center for Veterinary Medicine (CVM), comprehensive protocol design, and adherence to good documentation practices. The presentation also covers modern approaches like adaptive study designs and the acceptable use of foreign data or published literature. It delves into the nuances of CMC, focusing on ensuring product quality, consistency across batches, and maintaining good manufacturing practices (cGMP) throughout a drug’s lifecycle. Common submission gaps are addressed, providing guidance on avoiding delays and ensuring successful review outcomes, ultimately aiming to facilitate the approval of safe and effective animal drugs.

    Leave a Comment

    Your email address will not be published. Required fields are marked *